Get the Stockscreener App
485.77
1.80%
8.57
After Hours:
485.00
-0.77
-0.16%
United Therapeutics Corp stock is traded at $485.77, with a volume of 297.98K.
It is up +1.80% in the last 24 hours and up +16.05% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$477.20
Open:
$480.86
24h Volume:
297.98K
Relative Volume:
0.41
Market Cap:
$20.92B
Revenue:
$3.08B
Net Income/Loss:
$1.24B
P/E Ratio:
18.97
EPS:
25.6108
Net Cash Flow:
$1.07B
1W Performance:
+1.93%
1M Performance:
+16.05%
6M Performance:
+57.90%
1Y Performance:
+31.77%
1-Day Range:
$471.05
$486.20
1-Week Range:
$466.72
$486.20
52-Week Range:
$266.98
$486.20
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
485.77 | 20.55B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
127.89 | 54.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.50 | 44.92B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.06B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.99 | 28.42B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
Chmn Rothblatt Sells 8,000 ($3.8M) Of United Therapeutics Corp [UTHR] - TradingView
[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity - Stock Titan
Chmn Rothblatt Files To Sell 4,000 Of United Therapeutics Corp [UTHR] - TradingView
United Therapeutics Corporation (UTHR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Heatmap analysis for United Therapeutics Corporation and competitorsJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Why United Therapeutics Corporation stock is trending among retail tradersMarket Trend Review & Precise Buy Zone Tips - newser.com
How United Therapeutics Corporation (UTH) stock trades after earningsBear Alert & AI Powered Buy/Sell Recommendations - newser.com
Understanding United Therapeutics Corporation’s price movementMarket Activity Summary & Daily Technical Stock Forecast Reports - newser.com
Jefferies reiterates Buy rating on United Therapeutics stock, cites strong growth - Investing.com
How United Therapeutics Corporation stock benefits from global expansionEarnings Trend Report & Trade Opportunity Analysis Reports - newser.com
Pres Benkowitz Sells 22,500 ($10.6M) Of United Therapeutics Corp [UTHR] - TradingView
CFO Edgemond Sells 21,000 ($9.9M) Of United Therapeutics Corp [UTHR] - TradingView
How United Therapeutics Corporation (UTH) stock correlates with oil marketsWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
United Therapeutics stock hits all-time high of $479.78 By Investing.com - Investing.com South Africa
United Therapeutics stock hits all-time high of $479.78 - Investing.com
United Therapeutics posts record revenue but misses Q3 earnings expectations - MSN
Can technical indicators confirm United Therapeutics Corporation’s reversal2025 Technical Patterns & Risk Adjusted Swing Trade Ideas - newser.com
Will United Therapeutics Corporation benefit from macro trends2025 Market Trends & Detailed Earnings Play Strategies - newser.com
How United Therapeutics Corporation (UTH) stock reacts to stronger dollarRecession Risk & Risk Controlled Stock Alerts - newser.com
Rothblatt (United Therapeutics) sells $4.7m in UTHR stock By Investing.com - Investing.com Canada
United Therapeutics Executives Sell Shares - TradingView
United Therapeutics Executives Sell Shares Worth Over $13 Million - TradingView
3 Reasons Investors Love United Therapeutics (UTHR) - Finviz
United Therapeutics (UTHR): Stock Up 44.4%, Strong Growth & Cash FlowNews and Statistics - IndexBox
Is United Therapeutics Corporation (UTH) stock a top dividend aristocrat candidateJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Will United Therapeutics Corporation stock rally after Fed decisionsJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
United Therapeutics’ AI-Driven Study: A Potential Game-Changer for Pulmonary Hypertension Diagnosis - MSN
United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation - MSN
United Therapeutics CorporationCommon Stock (Nasdaq:UTHR) Stock Quote - Markets Financial Content
P/E Ratio Insights for United Therapeutics - Benzinga
Is United Therapeutics Corp Gaining or Losing Market Support? - Sahm
United Therapeutics Corporation (UTHR) Stock Forecasts - Yahoo! Finance Canada
UBS Maintains United Therapeutics (UTHR) Buy Recommendation - Nasdaq
United Therapeutics (NASDAQ:UTHR) CEO Sells $1,753,200.00 in Stock - MarketBeat
United Therapeutics CFO Sells Over $9 Million in Company Stock - TradingView
Will United Therapeutics Corporation stock benefit from upcoming earnings reportsQuarterly Investment Review & Advanced Technical Signal Analysis - newser.com
Access Investment Management LLC Makes New $2.14 Million Investment in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ: UTHR) sets Nov 10 & 18 talks at UBS, Jefferies; webcasts - Stock Titan
United Therapeutics Corporation $UTHR Position Lessened by Bessemer Group Inc. - MarketBeat
Combining machine learning predictions for United Therapeutics CorporationMarket Performance Recap & Verified Technical Trade Signals - newser.com
United Therapeutics Corporation (UTHR) Stock forecasts - Yahoo Finance UK
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease - The Joplin Globe
United Therapeutics (Nasdaq: UTHR) starts EXPAND with first UKidney xenotransplant - Stock Titan
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 20 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 21 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 20 '25 |
Sale |
478.38 |
4,000 |
1,913,524 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 21 '25 |
Sale |
474.64 |
4,000 |
1,898,558 |
130 |
1.61%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):